IKT News and Press, Inhibikase Therapeutics Inc. From 08/26/22

Penny stocks are shares of companies trading for less than $5, by definition. But what should you know about stocks priced even lower? Volatility and speculation tend to play leading roles, especially when there are active catalysts to consider. It might be rumors about a potential buyout o...

The U.S. Food and Drug Administration (FDA) cleared Inhibikase Therapeutics (IKT) application seeking to start a trial of IkT-001Pro to treat Chronic Myelogenous Leukemia (CML). The company said IkT-001Pro will be evaluated in a bioequivalence study, which will enroll ~64...

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia PR Newswire BOSTON and ATLANTA , Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT)...

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease PR Newswire BOSTON and ATLANTA , Aug. 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhib...

The following slide deck was published by Inhibikase Therapeutics, Inc. in conjunction with this event. For further details see: Inhibikase Therapeutics (IKT) Investor Presentation - Slideshow

Inhibikase Therapeutics, Inc. (IKT) Q2 2022 Earnings Conference Call August 15, 2022 8:00 a.m. ET CompanyParticipants Milton Werner - CEO Joseph Frattaroli - CFO Alex Lobo - Stern IR Conference Call Participants Danya Ben-Hail - JonesTrading Pre...

The following slide deck was published by Inhibikase Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Inhibikase Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q2 GAAP EPS of -$0.18. Revenue of $6.55K (-99.5% Y/Y). Cash and cash equivalents were $32.2 million as of June 30, 2022. The Company expects that existing cash and cash equivalents will be sufficient to fund it...

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity PR Newswire Company to host conference call and webcast on Monday, August 15, 2022 , at 8:00am ET BOSTON and ATLANTA , Aug. 12, 202...

Major earnings expected after the bell on Friday include: Sundial Growers   ( SNDL ) Beam Global   ( BEEM ) Virgin Orbit Holdings  ( VORB ) American Shared Hospital Services  ( AMS ) Inhibikase Therapeutics  ( IKT ...